[go: up one dir, main page]

LT2695609T - Per burną vartojamos citidino analogų kompozicijos ir jų panaudojimo būdai - Google Patents

Per burną vartojamos citidino analogų kompozicijos ir jų panaudojimo būdai

Info

Publication number
LT2695609T
LT2695609T LTEP13182721.4T LT13182721T LT2695609T LT 2695609 T LT2695609 T LT 2695609T LT 13182721 T LT13182721 T LT 13182721T LT 2695609 T LT2695609 T LT 2695609T
Authority
LT
Lithuania
Prior art keywords
oral
citidine
analogue
composition
oral composition
Prior art date
Application number
LTEP13182721.4T
Other languages
English (en)
Inventor
Jeffrey B. Etter
Mei Lai
Jay T. Backstrom
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40941609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2695609(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of LT2695609T publication Critical patent/LT2695609T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP13182721.4T 2008-05-15 2009-05-14 Per burną vartojamos citidino analogų kompozicijos ir jų panaudojimo būdai LT2695609T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5360908P 2008-05-15 2008-05-15
US20114508P 2008-12-05 2008-12-05
US15787509P 2009-03-05 2009-03-05

Publications (1)

Publication Number Publication Date
LT2695609T true LT2695609T (lt) 2020-02-10

Family

ID=40941609

Family Applications (5)

Application Number Title Priority Date Filing Date
LTEP13182721.4T LT2695609T (lt) 2008-05-15 2009-05-14 Per burną vartojamos citidino analogų kompozicijos ir jų panaudojimo būdai
LTEP20201105.2T LT3782611T (lt) 2008-05-15 2009-05-14 Citidino analogų peroralinės kompozicijos ir jų naudojimo būdai
LTEP19213148.0T LT3692983T (lt) 2008-05-15 2009-05-14 Citidino analogų peroralinės kompozicijos ir jų naudojimo būdai
LTEP09746975.3T LT2299984T (lt) 2008-05-15 2009-05-14 Peroralinės citidino analogų kompozicijos ir jų naudojimo būdai
LTEP20201143.3T LT3782612T (lt) 2008-05-15 2009-05-14 Geriamosios citidino analogų kompozicijos ir jų naudojimo būdai

Family Applications After (4)

Application Number Title Priority Date Filing Date
LTEP20201105.2T LT3782611T (lt) 2008-05-15 2009-05-14 Citidino analogų peroralinės kompozicijos ir jų naudojimo būdai
LTEP19213148.0T LT3692983T (lt) 2008-05-15 2009-05-14 Citidino analogų peroralinės kompozicijos ir jų naudojimo būdai
LTEP09746975.3T LT2299984T (lt) 2008-05-15 2009-05-14 Peroralinės citidino analogų kompozicijos ir jų naudojimo būdai
LTEP20201143.3T LT3782612T (lt) 2008-05-15 2009-05-14 Geriamosios citidino analogų kompozicijos ir jų naudojimo būdai

Country Status (34)

Country Link
US (12) US8846628B2 (lt)
EP (6) EP3782611B1 (lt)
JP (3) JP2011520880A (lt)
KR (1) KR101633134B1 (lt)
CN (3) CN105535008A (lt)
AR (1) AR071808A1 (lt)
AU (3) AU2009246926B2 (lt)
BR (1) BRPI0912717A2 (lt)
CA (3) CA3094580C (lt)
CL (2) CL2009001170A1 (lt)
CO (1) CO6300930A2 (lt)
CR (1) CR11789A (lt)
CY (3) CY1121350T1 (lt)
DK (5) DK3782612T3 (lt)
EC (1) ECSP10010665A (lt)
ES (5) ES2893785T3 (lt)
FI (1) FI3782612T3 (lt)
HR (5) HRP20231439T1 (lt)
HU (5) HUE064677T2 (lt)
IL (2) IL209307A (lt)
LT (5) LT2695609T (lt)
MX (2) MX363023B (lt)
MY (1) MY161593A (lt)
NI (1) NI201000193A (lt)
NZ (3) NZ602833A (lt)
PE (2) PE20142440A1 (lt)
PL (5) PL3692983T3 (lt)
PT (5) PT2299984T (lt)
RU (3) RU2476207C2 (lt)
SG (1) SG193206A1 (lt)
SI (5) SI2299984T1 (lt)
TW (3) TWI618538B (lt)
WO (1) WO2009139888A1 (lt)
ZA (1) ZA201008229B (lt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
JP2011505336A (ja) * 2007-11-01 2011-02-24 セルジーン コーポレイション 骨髄異形成症候群治療のためのシチジンアナログ
LT2695609T (lt) * 2008-05-15 2020-02-10 Celgene Corporation Per burną vartojamos citidino analogų kompozicijos ir jų panaudojimo būdai
US20150290228A1 (en) * 2008-05-15 2015-10-15 Jay T. BACKSTROM Oral formulations of cytidine analogs and methods of use thereof
EP2396007A1 (en) 2009-02-10 2011-12-21 Celgene International Sarl Methods for treating non-small cell lung cancer using 5-azacytidine
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US20110301102A1 (en) * 2010-06-07 2011-12-08 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
US8759303B2 (en) 2010-06-07 2014-06-24 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
CA2801891C (en) * 2010-06-07 2020-10-27 Abraxis Bioscience, Llc Combination therapy methods for treating proliferative diseases
CA2825152A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
EP2481813A1 (en) * 2011-02-01 2012-08-01 Centro di Riferimento Oncologico - Istituto Nazionale Tumori - Aviano Markers of cutaneous melanoma and uses thereof
BR112013025167A2 (pt) 2011-03-31 2019-09-24 Celgene Int Sarl processo para preparar 5-azacitidina, ou um sal, solvato, hidrato, ou seu polimorfo, sal de 5-azacitidina, 5-azacitidina, ou um sal, solvato, hidrato, ou polimorfo
TW201700103A (zh) * 2011-11-01 2017-01-01 西建公司 利用胞嘧啶核苷類似物之口服配方治療癌症的方法
AU2012321106C1 (en) 2011-11-03 2016-11-24 Takeda Pharmaceutical Company Limited Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
MX2015000804A (es) * 2012-07-20 2016-03-11 Star Biotechnology Llc Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1.
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
MX2016011810A (es) 2014-03-14 2017-04-27 Agios Pharmaceuticals Inc Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
PL3182996T3 (pl) 2014-08-22 2023-04-17 Celgene Corporation Sposoby leczenia szpiczaka mnogiego związkami immunomodulującymi w kombinacji z przeciwciałami
MX2017014987A (es) * 2015-05-22 2018-04-13 Novartis Ag Composiciones farmaceuticas.
CN108472291A (zh) 2015-10-15 2018-08-31 阿吉奥斯制药公司 用于治疗恶性肿瘤的组合疗法
PL3362066T3 (pl) * 2015-10-15 2022-05-02 Les Laboratoires Servier Terapia skojarzona do leczenia nowotworów złośliwych
US10695352B2 (en) * 2015-10-15 2020-06-30 Celgene Corporation Combination therapy for treating malignancies
JP7194021B2 (ja) 2015-12-03 2022-12-21 エピデスティニー，インコーポレイテッド デシタビン、５アザシチジンおよびテトラヒドロウリジンを含有する組成物およびその使用
WO2017180489A1 (en) 2016-04-12 2017-10-19 The Johns Hopkins University Quantitative determination of nucleoside analogue drugs in genomic dna or rna
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
EA039874B1 (ru) * 2019-06-06 2022-03-22 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно)
JP2022537384A (ja) 2019-06-20 2022-08-25 セルジーン コーポレーション ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン
BR112022007376A2 (pt) 2019-10-21 2022-07-05 Novartis Ag Terapias de combinação com venetoclax e inibidores de tim-3
CA3157665A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
US20230056470A1 (en) 2019-12-20 2023-02-23 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
EP4090335A1 (en) 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
CA3176543A1 (en) 2020-04-23 2021-10-28 Mark J. Suto Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof
CN115989229A (zh) 2020-07-23 2023-04-18 南方研究院 5-氮杂-4’-硫代-2’-脱氧胞苷的多晶型物
WO2022133323A1 (en) * 2020-12-18 2022-06-23 Southern Research Institute 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections
US20240229156A1 (en) 2021-03-12 2024-07-11 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
EP4419075A1 (en) 2021-10-19 2024-08-28 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
CN118903036B (zh) * 2024-10-10 2025-03-04 华夏罕见病药物研发(山东)有限公司 一种含尿苷的组合物的制备方法及其在治疗发育性癫痫性脑病50型中的应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913408A (en) 1956-12-28 1959-11-17 Dow Chemical Co Corrosion inhibitors for ferrous metals in aqueous solutions of non-oxidizing acids
GB1050899A (lt) 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
JPS59151784U (ja) 1983-03-30 1984-10-11 日産自動車株式会社 トラツクのリヤボデイ構造
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DK0397042T3 (da) 1989-05-10 1995-10-02 Hoffmann La Roche Fremstilling af isoquinolinderivater
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US5700640A (en) 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en) 1994-10-17 1996-07-23 Trojan Technologies Inc. Method of cleaning fouling materials from a radiation module
CN1268140A (zh) 1996-10-16 2000-09-27 Icn药品公司 单环l－核苷、类似物及其应用
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
DE69831335T3 (de) 1997-06-06 2015-01-15 Depomed, Inc. Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
US6803195B1 (en) 1999-07-02 2004-10-12 Ramot At Tel-Aviv University Ltd. Facile detection of cancer and cancer risk based on level of coordination between alleles
EP1236472A1 (en) 1999-07-16 2002-09-04 Amato Pharmaceutical Products, Ltd. Glycyrrhizin preparations for transmucosal absorption
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
IL150568A0 (en) 2000-02-04 2003-02-12 Depomed Inc A controlled release oral drug dosage form
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
EP1399159A4 (en) 2001-06-01 2007-02-14 Cytovia Inc 4-SUBSTITUTE-1- (ARYLMETHYLIDENE) THIOSEMICARBAZIDE, 4-SUBSTITUTE-1- (ARYLCARBONYL) THIOSEMICARBAZIDE AND ANALOGUES AS ACTIVATORS OF APOPTOSIS CAPSASES AND TRIGS, AND USE THEREOF
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030220254A1 (en) 2002-03-29 2003-11-27 Texas Tech University System Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
WO2004028454A2 (en) 2002-09-24 2004-04-08 Koronis Pharmaceuticals, Incorporated 1, 3, 5-triazines for treatment of viral diseases
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
CA2503150A1 (en) 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
JP2006516250A (ja) 2002-12-18 2006-06-29 サイトビア インコーポレイティッド カスパーゼ活性化剤およびアポトーシス誘導物質としての３，５−二置換−［１，２，４］−オキサジアゾールおよびそれらの誘導体ならびにそれらの使用
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
JP2006528952A (ja) 2003-05-21 2006-12-28 ノバルティス アクチエンゲゼルシャフト ヒストンデアセチラーゼ阻害剤と化学療法剤の組み合わせ
CN1964714B (zh) * 2003-08-29 2011-09-28 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
CN100374160C (zh) * 2004-11-22 2008-03-12 山东蓝金生物工程有限公司 一种含抗代谢类药物的抗癌药物组合物
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
NZ560879A (en) 2005-02-18 2010-04-30 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
SG160364A1 (en) 2005-03-07 2010-04-29 Bayer Schering Pharma Ag Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
CN100500212C (zh) * 2005-04-06 2009-06-17 山东蓝金生物工程有限公司 一种抗实体肿瘤药物组合物
US8058260B2 (en) 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
US20080057086A1 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
US7759481B2 (en) 2007-01-11 2010-07-20 Ivax Corporation Solid state forms of 5-azacytidine and processes for preparation thereof
EP2114152A1 (en) 2007-01-25 2009-11-11 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
JP5173298B2 (ja) 2007-07-25 2013-04-03 キヤノン株式会社 プリント配線板およびそれを用いた電子機器
EP2176279A4 (en) 2007-08-02 2012-01-11 Chemagis Ltd HIGH-PURITY, STABLE AZACYTIDINE AND METHODS OF PREPARATION
WO2009042767A1 (en) 2007-09-26 2009-04-02 Mount Sinai School Of Medicine Azacytidine analogues and uses thereof
EP2048151A1 (en) 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
JP2011505336A (ja) 2007-11-01 2011-02-24 セルジーン コーポレイション 骨髄異形成症候群治療のためのシチジンアナログ
LT2695609T (lt) 2008-05-15 2020-02-10 Celgene Corporation Per burną vartojamos citidino analogų kompozicijos ir jų panaudojimo būdai
WO2010014883A2 (en) 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
EP2520581A1 (en) 2008-08-06 2012-11-07 Sicor, Inc. Method for the determination the purity of 5-Azacytidine
AR073003A1 (es) 2008-08-08 2010-10-06 Scinopharm Taiwan Ltd Proceso para preparar 5-azacitosina nucleosidos y sus derivados
PL2361085T5 (pl) 2008-11-22 2018-12-31 F.Hoffmann-La Roche Ag Zastosowanie przeciwciała anty-vegf w połączeniu z chemioterapią w leczeniu raka sutka
US20110042247A1 (en) 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (it) 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina
CA2825152A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
BR112013025167A2 (pt) 2011-03-31 2019-09-24 Celgene Int Sarl processo para preparar 5-azacitidina, ou um sal, solvato, hidrato, ou seu polimorfo, sal de 5-azacitidina, 5-azacitidina, ou um sal, solvato, hidrato, ou polimorfo
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
TW201700103A (zh) 2011-11-01 2017-01-01 西建公司 利用胞嘧啶核苷類似物之口服配方治療癌症的方法

Also Published As

Publication number Publication date
US12053482B2 (en) 2024-08-06
CO6300930A2 (es) 2011-07-21
PL3782612T3 (pl) 2024-03-04
SG193206A1 (en) 2013-09-30
CY1122681T1 (el) 2020-10-14
RU2476207C2 (ru) 2013-02-27
IL209307A0 (en) 2011-01-31
HRP20190100T1 (hr) 2019-04-05
PT3692983T (pt) 2021-11-08
TW201729817A (zh) 2017-09-01
BRPI0912717A2 (pt) 2014-12-23
AU2015202884A1 (en) 2015-06-18
LT3782611T (lt) 2022-10-10
CA3094580A1 (en) 2009-11-19
PT3782611T (pt) 2022-11-18
MX2010012470A (es) 2010-12-02
JP2015110575A (ja) 2015-06-18
US20250082661A1 (en) 2025-03-13
PL2299984T3 (pl) 2019-07-31
ES2774226T3 (es) 2020-07-17
EP2299984A1 (en) 2011-03-30
JP2017137326A (ja) 2017-08-10
US20200101095A1 (en) 2020-04-02
EP4327888A2 (en) 2024-02-28
NI201000193A (es) 2011-08-01
HRP20231439T1 (hr) 2024-03-01
ES2969144T3 (es) 2024-05-16
US20230255996A1 (en) 2023-08-17
NZ602833A (en) 2014-04-30
TWI618538B (zh) 2018-03-21
AU2009246926A1 (en) 2009-11-19
TWI522103B (zh) 2016-02-21
EP3782612B1 (en) 2023-11-08
CA2761582A1 (en) 2009-11-19
MY161593A (en) 2017-04-28
US20150056280A1 (en) 2015-02-26
DK3782612T3 (da) 2024-01-15
CR11789A (es) 2011-02-21
US20220079964A1 (en) 2022-03-17
JP6426778B2 (ja) 2018-11-21
EP3782611A1 (en) 2021-02-24
HRP20200096T1 (hr) 2020-04-03
SI2695609T1 (sl) 2020-03-31
LT2299984T (lt) 2019-03-25
EP3692983A1 (en) 2020-08-12
KR20110015629A (ko) 2011-02-16
RU2012147739A (ru) 2014-05-20
RU2765076C2 (ru) 2022-01-25
CL2013001097A1 (es) 2013-11-29
DK2695609T3 (da) 2020-02-10
PL3782611T3 (pl) 2022-11-07
PT2695609T (pt) 2020-03-02
CN103479586A (zh) 2014-01-01
PT3782612T (pt) 2024-01-18
TW201006478A (en) 2010-02-16
DK3692983T3 (da) 2021-09-20
HUE064677T2 (hu) 2024-04-28
US20180153916A1 (en) 2018-06-07
EP2299984B1 (en) 2018-11-28
EP4327888A3 (en) 2024-05-22
CL2009001170A1 (es) 2010-06-04
EP3782611B1 (en) 2022-07-06
CA3094580C (en) 2021-05-18
SI3782611T1 (sl) 2022-10-28
US20230241086A1 (en) 2023-08-03
NZ623495A (en) 2015-08-28
US10220050B2 (en) 2019-03-05
IL209307A (en) 2016-02-29
NZ589437A (en) 2012-11-30
US11571436B2 (en) 2023-02-07
PE20142440A1 (es) 2015-01-28
DK2299984T3 (en) 2019-03-04
FI3782612T3 (fi) 2024-01-16
AU2009246926B2 (en) 2014-06-26
IL238087B (en) 2019-01-31
LT3782612T (lt) 2023-12-27
US10463683B2 (en) 2019-11-05
ES2712506T3 (es) 2019-05-13
HUE059635T2 (hu) 2022-12-28
LT3692983T (lt) 2021-11-10
ES2893785T3 (es) 2022-02-10
AU2015202884B2 (en) 2017-02-23
RU2018109222A (ru) 2019-09-17
US20150374732A1 (en) 2015-12-31
HRP20221064T1 (hr) 2022-11-11
CA3094590A1 (en) 2009-11-19
CN105535008A (zh) 2016-05-04
PT2299984T (pt) 2019-02-25
JP2011520880A (ja) 2011-07-21
ES2927556T3 (es) 2022-11-08
MX363023B (es) 2019-03-05
ECSP10010665A (es) 2011-01-31
SI2299984T1 (sl) 2019-04-30
HUE042825T2 (hu) 2019-07-29
PE20091971A1 (es) 2010-01-15
EP2695609A1 (en) 2014-02-12
JP6105547B2 (ja) 2017-03-29
CN103479586B (zh) 2017-03-01
CY1124720T1 (el) 2022-07-22
US20090286752A1 (en) 2009-11-19
EP3782612A1 (en) 2021-02-24
TW201513869A (zh) 2015-04-16
CY1121350T1 (el) 2020-05-29
RU2018109222A3 (lt) 2021-07-02
AU2013202665B2 (en) 2015-06-25
KR101633134B1 (ko) 2016-06-23
HUE055911T2 (hu) 2021-12-28
DK3782611T3 (da) 2022-09-05
US20220105118A1 (en) 2022-04-07
US10646503B2 (en) 2020-05-12
ZA201008229B (en) 2012-02-29
PL2695609T3 (pl) 2020-05-18
EP3692983B1 (en) 2021-08-11
US20200316099A1 (en) 2020-10-08
AR071808A1 (es) 2010-07-14
PL3692983T3 (pl) 2021-12-27
HRP20211398T1 (hr) 2021-12-10
SI3782612T1 (sl) 2024-02-29
WO2009139888A1 (en) 2009-11-19
US20190231803A1 (en) 2019-08-01
HUE047707T2 (hu) 2020-05-28
CN102099018A (zh) 2011-06-15
US8846628B2 (en) 2014-09-30
RU2010151428A (ru) 2012-06-20
SI3692983T1 (sl) 2021-11-30
CA2761582C (en) 2022-06-07
CN102099018B (zh) 2016-01-13
EP2695609B1 (en) 2019-12-11
AU2013202665A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
LT2695609T (lt) Per burną vartojamos citidino analogų kompozicijos ir jų panaudojimo būdai
LTPA2019003I1 (lt) Nauji junginiai ir kompozicijos ir jų panaudojimo būdai
PL2320911T3 (pl) Leki obkurczające naczynia krwionośne i sposoby ich wykorzystania
ZA201008887B (en) Oral compositions and uses thereof
BRPI0906980A2 (pt) Composição de derivados e maleatados
EP2254555A4 (en) APREPITANT FORMS WITH INCREASED SOLUBILITY AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
PL2119477T3 (pl) Kompozycja do leczenia kserostomii lub suchej jamy ustnej
ZA201007920B (en) Oral compositions and uses thereof
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
EP2473043A4 (en) ORAL CARE PROCESSES AND COMPOSITIONS WITH CHITOSANE DERIVATIVE COMPONENTS
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
EP2231665A4 (en) NEW COMPOSITIONS AND METHODS OF USE
PL2173345T3 (pl) Doustna formulacja metadoksyny
EP2241304A4 (en) ORAL DENTAL COMPOSITION
HK1257928A1 (zh) 四環素化合物的口服和注射製劑
PL2285450T3 (pl) Kompozycje do higieny jamy ustnej i sposoby
ZA201007091B (en) Vaccine compositions for the treatment of dengue fever and uses thereof
LT2320739T (lt) Farmacinės kompozicijos ir jų stabilizavimo būdai
DK2240154T3 (da) Kosmetisk sammensætning omfattende glycogentil anvendelse med fløjlsblød virkning
TH0901002159B (th) สูตรผสมของไซทิดีนแอนะลอกสำหรับให้ทางปาก และวิธีการใช้สูตรผสมดังกล่าว
TH126328B (th) องค์ประกอบสำหรับช่องปากและการใช้องค์ประกอบเหล่านี้
AU2008904468A0 (en) Vaccine composition and use of same
TH0901005521A (th) องค์ประกอบสำหรับใช้ในช่องปาก